While some people believe genetics and environmental factors are the leading causes, others are pushing back and saying that our diet is the most responsible. Chronic inflammation is such a broad topic that it is difficult to narrow down an argument for either side. What is more likely to be the case is a truth that lies somewhere in the middle. There is a good chance that all of these things will lead to the development of chronic inflammation which has been known to lead to other more serious diseases like cancer or heart disease.
Since inflammation leads to so many other health problems it has been an area of research for many pharmaceutical companies. Major names like Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Pfizer (NYSE: PFE) are all looking into developing a treatment for the issue. Others, like Ludwig Enterprises (OTC: LUDG), are using common genetic markers to revolutionize how we approach inflammation.
The Ludwig mRNA Inflammation Index is going to be a database where we can look at our genetic makeup to predict the early onset of more serious diseases. It also has the potential to develop treatments that work best for each individual’s genetic makeup, in what Ludwig calls choosing the best plan of care the first time. The index is powered by artificial intelligence and will provide insight into potential diseases long before symptoms appear in a patient.
Featured: $JNJ $ABBV $PFE $LUDG